Status:
COMPLETED
Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients
Lead Sponsor:
University Hospital, Ghent
Collaborating Sponsors:
KU Leuven
University Ghent
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Biologics, such as ixekizumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to...
Detailed Description
Patients will be included after siging informed consent. After inclusion, patients will continue on standard dosing schedule of ixekizumab (i.e. one loading dose of 2 subcutaneous injections (160 mg) ...
Eligibility Criteria
Inclusion
- Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
- Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
Exclusion
- Participants who have currently a predominant nonplaque form of psoriasis
- Participants who are pregnant, nursing or planning a pregnancy
- Participants who are unable or unwilling to undergo multiple venapunctures
- Participants who are treated according to a different dosing schedule than standard dosing of ixekizumab
Key Trial Info
Start Date :
May 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04083612
Start Date
May 4 2020
End Date
December 31 2023
Last Update
September 19 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
AZ Maria Middelares
Ghent, Oost-Vlaanderen, Belgium, 9000
2
AZ Sint-Lucas
Ghent, Oost-Vlaanderen, Belgium, 9000
3
University Hospital of Ghent
Ghent, Oost-Vlaanderen, Belgium, 9000
4
Private Practice Dermatology
Maldegem, Oost-Vlaanderen, Belgium, 9990